Keyzell and Lãberit join forces to develop artificial intelligence to personalize cancer treatments

1 2 1024x576 1
  • In 2020 almost 10 million people died from cancer and each year more than 19 million new cases are added worldwide
  • The Spanish start up Keyzell is committed to research and technology through blockchain and AI to improve cancer treatments and is supported by Lãberit’s multinational experience.

Madrid, February 18, 2022. KeyZell, a Spanish biotechnology company focused on the discovery and development of a new generation of anticancer drugs, as well as an innovative artificial intelligence system for oncology precision medicine, has signed an agreement of collaboration with the multinational Lãberit to continue with the development of a system based on artificial intelligence to analyze biomarkers and personalize cancer treatments.

At KeyZell, we are convinced that this is an important step to lead precision medicine in the oncology sector in the coming years. It is a really important step, which can help thousands of patients not have to go through aggressive treatments such as chemotherapy or radiotherapy unnecessarily, and to be able to initially treat the patient with the treatment with the highest probability of success”, says Jose del Corral, CEO of the company.

The system, named O.P.S. (Oncology Precision System), aims to increase efficiency, productivity, and clinical confidence in diagnosing the best treatment for cancer patients. The goal is to achieve an intelligent and automated workflow that provides information processing and interpretation capable of converting data into actionable information and extracting the medical oncology knowledge necessary to offer the most appropriate treatment against cancer according to the unique characteristics of each patient.

With this system we hope to generate predictions about tailored treatments, and we also hope to significantly increase the life expectancy and quality of life of patients,” says Del Corral.

Digital transformation in the health sector today is one more step towards improving treatments. With this agreement, we can continue to advance in the research and application of artificial intelligence to cancer treatments and gradually achieve a cultural readaptation of the entire sector to this new world that opens up a wide range of possibilities for medicine, such as technology”, points out Juan Tatay, Account Manager eHealth at Lãberit.

See here the complete article of Diario de Sevilla.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Recent news

Follow us on the networks

Subscribe to our newsletters

You will only receive notifications about new news and updates.

More news

KeyZell awarded with the Andalucía Excelente prize, best Biotechnology company 2022.

KeyZell received the Andalucía Excelente Award as the best Biotechnology company 2022. KeyZell, awarded for its commitment to create a new future for oncology, through …

Read more →

Fourier Intelligence, iRhythm and KeyZell are the most internationally recognized companies for revolutionizing the health sector

Health Tech World has released a compilation of the top 50 health technology innovators of 2022 who stand out for their unique innovation, outstanding technology …

Read more →

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe”

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe” in the seventh edition of the “International Life Sciences Awards 2022“. This event …

Read more →

KeyZell continues to advance in the development of its Artificial Intelligence tool

The biotech startup KeyZell has officially announced the launch of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for precision medicine …

Read more →

Revealed: The Health Tech World Top 50 Innovators of 2022

Health Tech World has announced its Top 50 health tech innovators of 2022. Here are the top picks of health tech companies who stand out …

Read more →

The capital dresses up for science

The European Association of Economy and Competitiveness celebrates the second edition of the Isaac Peral National Award for Research, Science and Innovation The investigation was …

Read more →

Artificial intelligence: key to optimizing clinical decisions in cancer patients

“The OPS (Oncology Precision System) starts from the genetic characteristics of each patient and is capable of proposing the best combination of treatments currently available …

Read more →

KeyZell boosts its cancer treatments

Receive an award for an Artificial Intelligence development.  KeyZell promotes its cancer treatments and for this it has received an award in the II Edition …

Read more →

KeyZell Awarded for Treating Cancer with Biotechnology, Artificial Intelligence

06.28.2022 2:48 pm Biotechnological startup Keisel has been honored at the second edition of the Isaac Perel National Research, Science and Innovation Awards organized by …

Read more →